Simulations Plus - SLP Stock Forecast, Price & News

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.

Simulations Plus Trading Down 1.4 %

Shares of NASDAQ:SLP traded down $0.88 on Tuesday, reaching $64.22. 2,623 shares of the company traded hands, compared to its average volume of 134,285. The company has a 50 day moving average of $55.01 and a 200 day moving average of $48.30. The stock has a market capitalization of $1.30 billion, a PE ratio of 114.21 and a beta of 0.42. Simulations Plus has a fifty-two week low of $35.18 and a fifty-two week high of $67.59.

Simulations Plus (NASDAQ:SLP - Get Rating) last issued its earnings results on Wednesday, July 6th. The technology company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.17 by $0.03. The business had revenue of $14.96 million for the quarter, compared to the consensus estimate of $14.33 million. Simulations Plus had a net margin of 22.74% and a return on equity of 6.91%. The business's revenue for the quarter was up 17.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.18 EPS. As a group, research analysts expect that Simulations Plus will post 0.64 earnings per share for the current year.

Simulations Plus Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 1st. Stockholders of record on Monday, July 25th were paid a $0.06 dividend. The ex-dividend date of this dividend was Friday, July 22nd. This represents a $0.24 dividend on an annualized basis and a dividend yield of 0.37%. Simulations Plus's dividend payout ratio (DPR) is presently 42.11%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Craig Hallum upped their price objective on shares of Simulations Plus from $55.00 to $60.00 and gave the company a "buy" rating in a research note on Thursday, July 7th. TheStreet raised shares of Simulations Plus from a "c+" rating to a "b-" rating in a research note on Friday, July 22nd.

Insider Activity at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 17,461 shares of the company's stock in a transaction dated Tuesday, June 28th. The shares were sold at an average price of $48.00, for a total value of $838,128.00. Following the completion of the transaction, the director now owns 4,140,173 shares in the company, valued at approximately $198,728,304. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director Walter S. Woltosz sold 17,461 shares of Simulations Plus stock in a transaction on Tuesday, June 28th. The stock was sold at an average price of $48.00, for a total transaction of $838,128.00. Following the transaction, the director now owns 4,140,173 shares in the company, valued at $198,728,304. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Walter S. Woltosz sold 20,000 shares of the business's stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of $61.19, for a total value of $1,223,800.00. Following the completion of the transaction, the director now owns 4,117,634 shares in the company, valued at approximately $251,958,024.46. The disclosure for this sale can be found here. Insiders sold a total of 57,461 shares of company stock valued at $3,021,728 in the last quarter. Insiders own 23.08% of the company's stock.